Financial Performance Summary
Consolidated Financial Highlights (₹ in millions):
| Metric | Q1 FY27 | Q1 FY26 | Growth % |
| Revenues | 9,464 | 7,916 | 19.5% |
| EBITDA* | 2,047 | 1,286 | 59.2% |
| EBITDA* % | 21.6% | 16.2% | |
| PAT | 793 | 369 | 114.9% |
*EBITDA refers to EBITDA excluding ESOP costs
Key Performance Drivers
- Revenue growth of 19.5% year-over-year to ₹9,464 million
- Significant EBITDA margin expansion of 540 basis points from 16.2% to 21.6%
- Profit After Tax more than doubled with 114.9% growth to ₹793 million
- Net Debt to EBITDA ratio maintained at 0.1x, indicating strong balance sheet position
Strategic Developments
The company completed the acquisition of Bio For Life in Italy, which represents a strategic focus on the companion animal segment. This acquisition provides market access and a platform to launch the company's product portfolio in key European markets.
Management Commentary
Dr Hari Babu Bodepudi, Managing Director and Group CEO, stated: "Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy."
Business Overview
Viyash Scientific Limited is globally among top-25 Animal Health companies with over 3,000 employees. The company is an integrated pharmaceutical company with a portfolio of formulations and APIs for human and veterinary use, serving customers in 100+ countries. The company and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies including USFDA, EUGMP, WHO, TGA.
Upcoming Events
The Company will conduct an Earnings call at 3:30 PM IST on August 12, 2026 where the Management will discuss the Company's performance and answer questions from participants. Dial-in numbers: +91 22 6280 1263 or +91 22 7115 8213.